DISCONTINUATION RECORD
Selank Withdrawal: What the Research Says
Russian short-course studies emphasize the absence of rebound anxiety. Forum reports describe milder mood dips. Long-term human discontinuation data does not exist in the published record.
Reported discontinuation effects
Selank withdrawal in the published Russian literature is framed by what it does not produce. The principal claim across the trial-era papers is the absence of rebound anxiety following short (7-14 day) intranasal courses [1]. That framing is deliberately positioned against benzodiazepine discontinuation, where rebound anxiety is a known clinical phenomenon. The Zozulia (2008) trial reported a benign acute discontinuation profile across its 14-day arm [1].
Forum and user reports occasionally describe mild mood dips on cessation. These reports are anecdotal, not controlled-trial data, and do not appear in the indexed literature. We document them only because the question is asked frequently enough to warrant a direct answer.
WHAT THE RODENT WITHDRAWAL MODELS SHOW
What the rodent withdrawal models show
The withdrawal story in the rodent literature is not about Selank withdrawal — it is about Selank as an attenuator of withdrawal from other substances. Three published rodent studies document this directly.
Morphine withdrawal: Selank reduced aversive signs of morphine withdrawal in rats, consistent with the molecule's documented opioid-system involvement and naloxone-reversible behavioral profile [12][21].
Alcohol withdrawal: Selank was efficacious during modeling of withdrawal syndrome in rats with stable alcoholic motivation, reducing anxiety- and depression-like behavior in the abstinence phase [13].
Ethanol sensitization: Selank inhibited ethanol-induced hyperlocomotion and blunted the development of behavioral sensitization in DBA/2 mice [14].
These are pharmacological-action studies, not Selank-discontinuation studies. They speak to mechanism, not to what happens when Selank itself stops.
LONG-TERM DISCONTINUATION: WHAT IS NOT KNOWN
Long-term discontinuation: what is not known
Long-term human Selank discontinuation data is absent from the published literature. The longest controlled human exposure documented in English-PubMed-indexed sources is the Zozulia (2008) 14-day intranasal course in 62 patients [1]. Beyond that window, controlled human discontinuation data does not exist.
The Russian Federation registration covers short-course pharmacopoeia use. The molecule is not approved for human use in any other jurisdiction. Chronic indefinite Selank exposure is not characterized in the published trial record, and chronic-exposure discontinuation is correspondingly uncharacterized.
That absence is the honest framing. The literature does not document a Selank withdrawal syndrome. It also does not document long-term safety. Both statements are true and neither is reassuring about long-term use.
Regulatory framing
Selank is registered as a pharmaceutical in the Russian Federation only. It is not approved by the FDA, EMA, MHRA, or TGA. In the United States it is sold strictly as a research chemical. Russian product labeling lists pregnancy and known peptide allergy as contraindications; outside Russia, no regulatory body has issued discontinuation guidance because no regulatory body has approved Selank for human use.